Introduction
============

Breast cancer (BC) ranks as the top leading malignant tumors among females, and also accounts for the most common cause of tumor-related mortality in females worldwide ([@b1-mco-0-0-1890]--[@b6-mco-0-0-1890]). Approximately 20--30% of BC cases develop metastases ([@b7-mco-0-0-1890]), while, \~50% of patients will suffer from BC liver metastasis (BCLM) ([@b8-mco-0-0-1890],[@b9-mco-0-0-1890]). The presence of liver metastasis has markedly worsened the prognosis of patients, and the median survival was reported to be 3.8--29 months ([@b10-mco-0-0-1890]--[@b13-mco-0-0-1890]).

However, several studies have previously summarized prognostic factors and survival outcomes associated with BCLM during the palliative treatment for metastasis ([@b10-mco-0-0-1890]--[@b18-mco-0-0-1890]). In addition, many previous studies have conducted analysis using a low number of patients receiving treatment in medical centers. Such studies have analyzed overall survival (OS) based on the conventional Cox proportional models, which is less reliable than the competing risk model.

Population-based epidemiological studies on clinical outcome predictors are lacking at present. The characteristics of patients, as well as the prognosis factors among patients have added to the difficulty in assessing the prognosis and treating patients, and thus needs further study. Therefore, the population-based prediction of prognosis for newly diagnosed BCLM is required for decision-making for the clinical treatment of BC.

A competing risk analysis was conducted in the present study to examine the association between tumor subtype and other prognostic factors, and the OS for BCLM cases collected from the Surveillance, Epidemiology and End Results (SEER) program. Furthermore, nomograms were utilized to visualize the Cox regression models, and to predict the prognosis for cancer cases. Moreover, we constructed a convenient nomogram to assess survival.

Materials and methods
=====================

### Study design

Data had been collected based on the SEER program, which had covered \~30% of the population of the United States of America. At present, SEER contains data regarding the treatment, incidence and survival of various types of cancer. We were approved to access the research data files (reference no. 16136-Nov2016), and data regarding with/without liver metastasis in newly diagnosed BC patients were collected from 2010 to 2014, since the metastatic sites at first diagnosis and molecular subtypes were available from 2010. A total of 218,951 cases diagnosed with BC from 2010 to 2014 were identified from the SEER database (<https://seer.cancer.gov/>). Patients with unknown liver metastasis status at the time of diagnosis were excluded from analysis (n=4,503), as a result, a cohort of 214,088 cases were enrolled for further analysis. Of note, 2,441 of these cases had been diagnosed with BCLM. Then, patients that were followed up for \<1 month (n=340) or had unknown survival time (n=3) were excluded, leaving 2,098 patients eligible for survival analysis ([Fig. 1](#f1-mco-0-0-1890){ref-type="fig"}). All parameters adopted in this paper had been identified from recent studies ([@b19-mco-0-0-1890]--[@b23-mco-0-0-1890]), which included the year of diagnosis, sex, age, marital status, race, tumor size, insurance status, tumor grade, laterality, nodal stage, surgery, site of metastasis, tumor subtype, cause of mortality, vital status, as well as months of survival. In addition, patients were stratified by the BC subtype as human epidermal growth factor receptor 2 (Her2; -)/hormone receptor (HR; +), Her2(+)/HR(+), Her2(+)/HR(−), or triple-negative (TNBC). Patients were followed with a median of 12 months (1--59 months).

In the present study, we did not enroll patients and the data collected from the SEER database did not contain personally identifiable information; therefore, informed consent was unnecessary. We obtained approval from the Ethical Committee and the Institutional Review Board of our University Cancer Center.

### Statistical analysis

Baseline categorical variables were compared using a Fisher\'s exact test or χ^2^ test. OS had been selected as the primary endpoint, which was calculated as the duration from the diagnosis of BC to mortality from all causes or the final follow-up in censored cases. Differences in OS were evaluated through Kaplan-Meier analysis, followed by a log-rank test. Furthermore, the multivariable Cox proportional hazards model was generated, and hazard ratios (HRs) with the corresponding 95% confidence intervals (CIs) were subsequently computed. To evaluate BC-specific mortality, the Fine and Gray\'s competing risk model was adopted, since its eventual failure could be attributed precisely to cancer-associated mortality. Additionally, the nomogram was also constructed through the R project rms package (<https://CRAN.R-project.org/package=rms>). In addition, model discriminating ability and stability had been computed using c-statistics and bootstrapping. Subsequently, calibration plots were generated for comparing the event rate among the population, as well as that estimated through the model for patients at some time. All tests were two-tailed; P\<0.05 was considered to indicate a statistically significant difference. STATA 12.0 (StataCorp LP) and R (version 3.4.1; R Foundation) were applied for all statistical analyses using the cmprsk package (version 2.2--7).

Results
=======

### Patient features

Data from a total of 2,098 patients with an initial diagnosis of BCLM from 2010 to 2014 were recruited for analysis in the presented study. The age of patients ranged from 24--99 years, with a median of 59 years. At the time of diagnosis, 571 (27.2%) cases exhibited metastasis only in the liver, while 799 (38.1%) also had bone metastases, 739 (35.2%) had concurrent lung metastases, while 190 (9.1%) had brain and liver metastases. A majority of cases were of stage III/IV (45.7%; n=959). In cases whose BC subtype was known, 42.2% (n=886) had Her2(−)/HR(+), 12.8% (n=268) had Her2(+)/HR(−), 19.1% (n=401) had Her2(+)/HR(+), and 13.5% (n=284) had TNBC ([Table I](#tI-mco-0-0-1890){ref-type="table"}).

Patients had been distributed based on tumor subtype and differences in the whole population were significant. Patients who developed TNBC liver metastasis were associated with advanced tumor stage (P\<0.001), increased risks of bone (P\<0.001), lung (P\<0.001) and brain metastases (P=0.042), higher rate of surgery (P\<0.001), and reduced rate of small tumor size (P=0.040), and increased risk of mortality (P\<0.001). By contrast, patients with Her2(+)/HR(−) only had a higher rate of liver metastasis (P\<0.001).

### OS analysis

Patients were followed up for 1--59 months, with a median of 12 months; 1,179 cases had succumbed \[including 498 with Her2(−)/HR(+), 124 with Her2(+)/HR(−), 155 with Her2(+)/HR(+) and 219 with TNBC\]. The median OS of the whole population was 20 months (95% CI, 18.2--21.8 months). In addition, 31.8, 23.1 and 13.9% patients were alive at 3, 4 and 5 years of follow up, respectively ([Fig. 2](#f2-mco-0-0-1890){ref-type="fig"}). Differences in OS were statistically significant; TNBC liver metastasis exhibited the most dismal prognosis (median OS was 15 months; 95% CI, 13.4--16.6 months), while, the median OS for Her2(+)/HR(+) BC was 51 months (95% CI, not available; P\<0.001; [Fig. 3A](#f3-mco-0-0-1890){ref-type="fig"}). Additionally, a plot of the estimated cumulative incidence function for cancer-specific cause of failure was also generated ([Fig. 3B](#f3-mco-0-0-1890){ref-type="fig"}). Cases with the only metastatic site in the liver were associated with better prognosis (median OS, 33 months; 95% CI, 24.0--42.0 months) than those with metastases at other sites (median OS, 24 months; 95% CI, 20.2--27.8 months; P\<0.001; [Fig. 4A](#f4-mco-0-0-1890){ref-type="fig"}). Similarly, patients with bone metastases (median OS, 24.0 months; 95% CI, 19.6--28.4 months) had dismal survival compared with those with no bone metastasis (median OS, 31.0 months; 95% CI, 26.0--36.0 months; P=0.003; [Fig. 4B](#f4-mco-0-0-1890){ref-type="fig"}); those with lung metastasis (median OS, 22.0 months; 95% CI, 15.5--28.5 months) had poor survival than those with no lung metastasis (median OS, 30.0 months; 95% CI, 25.5--34.5 months; P=0.001; [Fig. 4C](#f4-mco-0-0-1890){ref-type="fig"}); those with brain metastasis (median OS, 4.0 months; 95% CI, 1.2--6.8 months) had poor survival relative to those with no brain metastasis (median OS, 27.0 months; and 95% CI, 23.5--30.5 months; P=0.030; [Fig. 4D](#f4-mco-0-0-1890){ref-type="fig"}). However, differences in OS between left (median OS, 26.0 months; 95% CI, 20.0--32.0 months) and right BC (median OS, 27.0 months; 95% CI, was 23.4--30.6 months; P=0.616) was of no statistical significance; negative (median OS, 33.0 months; 95% CI, 24.0--42.0 months) and positive nodes (median OS, 26.0 months; 95% CI, 22.4--29.6 months; P=0.360) was not statistically significant. Furthermore, OS was decreased in older patients (\>64 years) (P\<0.001), and those of unmarried status (P=0.018), greater tumor size (\>50 mm) (P=0.036), advanced stage (P=0.033), without surgery (P=0.009), metastases at other sites (P\<0.001), as well as TNBC subtype (P\<0.001) ([Table II](#tII-mco-0-0-1890){ref-type="table"}).

### Prognostic factors and nomogram construction

Multivariate analysis was conducted using the Cox proportional hazard model, which suggested that age at diagnosis, marital status, surgery, bone metastasis, brain metastasis, and tumor subtype were independent risk factors of OS. Nonetheless, gender, nationality, insurance, tumor size, laterality, nodal stage, as well as lung metastasis showed no marked association with OS ([Table III](#tIII-mco-0-0-1890){ref-type="table"}). BC-specific mortality among BCLM patients was also presented in [Table III](#tIII-mco-0-0-1890){ref-type="table"}. Of note, age at diagnosis (P\<0.001), marital status (P=0.042), surgery (P=0.017), bone metastasis (P=0.048), brain metastasis (P=0.002), and tumor subtype (P\<0.001) had been identified to be independent prognosis factors.

A nomogram for prognosis prediction was constructed using the Cox regression model, which had incorporated the aforementioned independent prognostic factors ([Fig. 5A](#f5-mco-0-0-1890){ref-type="fig"}). Specifically, bootstrapping was utilized for model internal validation. The C-index in predicting OS was 0.685 (95% CI, 0.650--0.720); model stability and internal validation had been investigated with 1,000 bootstrap samples. In addition, calibration curves of survival at 6, 12 and 36 months following diagnosis were presented in [Fig. 5B-D](#f5-mco-0-0-1890){ref-type="fig"}, respectively. The results predicted by the nomogram corresponded to the actual observations.

Discussion
==========

The composition of the investigated liver metastasis of the newly diagnosed BC patients was described in the current research; meanwhile, the survival for these cases was also characterized based on tumor subtypes of BC and metastatic sites. Data were generated based on the SEER program, which included \~30% of the US population; thus, our findings may reflect the experience of the real world population. In addition, Fine and Gray\'s competing risk model based on subdistribution hazards was also recommended to analyze cancer-associated mortality ([@b24-mco-0-0-1890]). Zhao *et al* ([@b25-mco-0-0-1890]) identified the prognostic factors of patients with breast cancer and liver metastasis from 2010 to 2014 using univariate and multivariate Cox regression analyses. Of note, there are several advantages in our research. We used Fine and Gray\'s competing risks model in addition to Cox regression analysis, which to the best our knowledge, has not been reported. We also built a nomogram to predict patient prognosis, which may provide novel information useful to physicians. To the best of our knowledge, this is the first study to conduct competing risk analysis on BCLM with population-based data. In this context, it is of crucial importance to assess the prognostic factors and outcomes of newly diagnosed patients with BCLM at the population-based level.

According to our results, the median OS was 20 months; 31.8, 23.1 and 13.9% patients were alive at 3, 4, and 5 years after diagnosis, respectively, irrespective of the dismal prognosis for patients with BCLM. However, the prognosis differed greatly among the published articles. For instance, Golse and Adam ([@b7-mco-0-0-1890]) suggested that BCLM patients receiving surgery were had a median OS of 25--70 months, along with the 5-year survival rate of 20--60%. Wang *et al* ([@b26-mco-0-0-1890]) had investigated clinical studies published from 2000 to 2017 concerning transarterial chemoembolization (TACE) for BCLM, in which 519 patients were involved, with a median OS for cases receiving TACE of 7.3--47.0 months. Tewes *et al* ([@b27-mco-0-0-1890]) had retrospectively analyzed patients with liver-predominant metastatic BC receiving hepatic arterial infusion chemotherapy, and their results suggested that the median OS was 7 months (range, 1--37 months). Nevertheless, it should be noted that patients were of an advanced stage of disease, with no further systemic treatment available. Moreover, Wang *et al* ([@b28-mco-0-0-1890]) had studied the clinical effects of ablation plus TACE on treating BCLM; 50 patients in the TACE group had a median survival time of 11.9 months, while 38 in the combined groups had a markedly longer median survival time of 15.6 months.

Similar to previous studies ([@b17-mco-0-0-1890],[@b29-mco-0-0-1890],[@b30-mco-0-0-1890]), our investigation showed that OS differed greatly depending on different subtypes, among which, Her2(+)/HR(+) BC had the most optimal survival (median survival of 51 months). TNBC patients were associated with the worst prognosis (median survival of 15 months). Relative to Her2(−)/HR(+) cases, the risk of death among Her2(+)/HR(+) cases was reduced by 54.4%, while that among TNBC cases was increased by 93.1%. Our data were consistent with prior studies analyzing the effects of tumor subtype on the OS for patients. Similarly, for brain metastasis of BC ([@b19-mco-0-0-1890],[@b20-mco-0-0-1890]), the Her2(+)/HR(+) subtype exhibited the most favorable prognosis, while the TNBC subtype had the worst survival. However, Her2(+)/HR(−) patients had exhibited improved survival than Her2(−)/HR(+) in BCLM; opposing findings were reported for patients with brain metastases.

In addition to tumor subtypes, the metastatic site involved was another crucial factor for survival ([@b7-mco-0-0-1890]). In accordance with Wang *et al* ([@b26-mco-0-0-1890]), our study suggested that, patients who had liver metastasis alone were associated with significantly improved prognosis to those developing metastases in the liver and other sites. Furthermore, the Her2(+)/HR(−) subtype was significantly related to the development of liver metastases alone, which may partly explain for the longer survival times for patients with Her2(+)/ HR(−). Univariate analysis suggested that, lung metastases could negatively affect the OS, but differences in all-cause mortality or the tumor-specific mortality of lung metastasis was not statistically significant upon Cox proportional hazard model analysis. Therefore, further investigation into the influence of lung metastases in BCLM is warranted.

Several limitations should be noted in this study. Firstly, the SEER program collected data regarding disease at initial diagnosis alone, while patients could then develop liver metastasis during their course of disease. Secondly, there may be some bias in treatment, which was not mentioned within the SEER program. Lastly, data regarding the number of metastases, performance status and comorbidities were unavailable from the SEER program.

Regardless of the aforementioned limitations, this study may provide novel insight into the epidemiology of liver metastasis among newly diagnosed BC patients. In addition, the prognostic data regarding tumor subtype, as well as the metastatic sites in the current analysis could provide important clinical knowledge for BCLM cases. Importantly, the efficient nomogram may also permit the assessment of prognosis for every BCLM patient. Nevertheless, clinical studies should be conducted in the future to verify our findings.
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![Kaplan-Meier curve of overall survival for the entire population.](mco-11-03-0259-g01){#f2-mco-0-0-1890}

![Kaplan-Meier curve of overall survival based on tumor subtype. (A) P\<0.001 upon log-rank test. (B) Estimated cumulative incidence curves for each combination of competing events and tumor subtypes. Solid lines, cancer-specific mortality; broken lines, death due to other reasons. Her2, human epidermal growth factor receptor 2; HR, hormone receptor.](mco-11-03-0259-g02){#f3-mco-0-0-1890}

![Kaplan-Meier curves of overall survival based on different metastatic sites. (A) Patients who have liver metastasis alone vs. those who have metastases in liver as well as other sites, P\<0.001 upon log-rank test. (B) Patients who have bone metastasis vs. those with no bone metastasis, P\<0.001 upon log-rank test. (C) Patients who have lung metastasis vs. those with no lung metastasis, P\<0.001 upon log-rank test. (D) Patients who have brain metastasis vs. those with no brain metastasis, P\<0.001 upon log-rank test.](mco-11-03-0259-g03){#f4-mco-0-0-1890}

![Survival prediction using the nomogram method. (A) Overall survival nomogram for breast cancer liver metastasis. Calibration curves to predict the survival for patients at (B) 6, (C) 12 and (D) 36 months among the study cohort. Her2, human epidermal growth factor receptor 2; HR, hormone receptor.](mco-11-03-0259-g04){#f5-mco-0-0-1890}

###### 

Patient characteristics according to tumor subtypes.

                                Tumor subtypes^[a](#tfn1-mco-0-0-1890){ref-type="table-fn"}^                                                                                  
  ----------------------------- -------------------------------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------- ------- -------------------------------------------------------
  All patients                                                                                 886    42.2   268    12.8   401    19.1   284    13.5   259    12.3    2,098   100.0
  Year of diagnosis                                                                                                                                                           
    2010                        168                                                            19.0   48     17.9   80     20.0   51     18.0   68     26.3   415     19.8    0.732
    2011                        184                                                            20.8   58     21.6   72     18.0   55     19.4   53     20.5   422     20.1    
    2012                        181                                                            20.4   53     19.8   103    25.7   61     21.5   47     18.1   445     21.2    
    2013                        192                                                            21.7   57     21.3   72     18.0   59     20.8   52     20.1   432     20.6    
    2014                        161                                                            18.2   52     19.4   74     18.5   58     20.4   39     15.1   384     18.3    
  Age (years)                                                                                                                                                                 
    \<50                        212                                                            23.9   81     30.2   126    31.4   74     26.1   36     13.9   529     25.2    \<0.001^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    50--64                      340                                                            38.4   118    44.0   177    44.1   114    40.1   108    41.7   857     40.8    
    \>64                        334                                                            37.7   69     25.7   98     24.4   96     33.8   115    44.4   712     33.9    
  Sex                                                                                                                                                                         
    Male                        6                                                              0.7    1      0.4    4      1.0    2      0.7    6      2.3    19      0.9     0.288
    Female                      880                                                            99.3   267    99.6   397    99.0   282    99.3   253    97.7   2,079   99.1    
  Race                                                                                                                                                                        
    Caucasian                   631                                                            71.2   190    70.9   286    71.3   185    65.1   200    77.2   1492    71.1    0.010^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    African descent             157                                                            17.7   50     18.7   72     18.0   77     27.1   41     15.8   397     18.9    
    Others                      94                                                             10.6   28     10.4   43     10.7   22     7.7    17     6.6    204     9.7     
    Unknown                     4                                                              0.5    0      0.0    0      0.0    0      0.0    1      0.4    5       0.2     
  Marital status                                                                                                                                                              
    Unmarried                   227                                                            25.6   51     19.0   111    27.7   61     21.5   61     23.6   511     24.4    0.023^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    Married                     605                                                            68.3   207    77.2   267    66.6   206    72.5   184    71.0   1,469   70.0    
    Unknown                     54                                                             6.1    10     3.7    23     5.7    17     6.0    14     5.4    118     5.6     
  Insurance status                                                                                                                                                            
    Uninsured                   28                                                             3.2    3      1.1    21     5.2    13     4.6    17     6.6    82      3.9     0.025^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    Insured                     840                                                            94.8   262    97.8   373    93.0   265    93.3   232    89.6   1,972   94.0    
    Unknown                     18                                                             2.0    3      1.1    7      1.7    6      2.1    10     3.9    44      2.1     
  Size (mm)                                                                                                                                                                   
    ≤20                         133                                                            15.0   36     13.4   62     15.5   35     12.3   35     13.5   301     14.3    0.040^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    21--50                      331                                                            37.4   104    38.8   168    41.9   100    35.2   60     23.2   763     36.4    
    \>50                        243                                                            27.4   83     31.0   102    25.4   108    38.0   49     18.9   585     27.9    
    Unknown                     179                                                            20.2   45     16.8   69     17.2   41     14.4   115    44.4   449     21.4    
  Grade                                                                                                                                                                       
    I                           72                                                             8.1    1      0.4    6      1.5    3      1.1    10     3.9    92      4.4     \<0.001^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    II                          340                                                            38.4   59     22.0   118    29.4   37     13.0   33     12.7   587     28.0    
    III/IV                      289                                                            32.6   168    62.7   218    54.3   216    76.1   68     26.3   959     45.7    
    Unknown                     185                                                            20.9   40     14.9   59     14.7   28     9.9    148    57.1   460     21.9    
  Laterality                                                                                                                                                                  
    Left                        438                                                            49.4   139    51.9   207    51.6   148    52.1   109    42.1   1,041   49.6    0.972
    Right                       406                                                            45.8   124    46.3   189    47.1   130    45.8   98     37.8   947     45.1    
    Bilateral, single primary   4                                                              0.5    2      0.7    1      0.2    2      0.7    5      1.9    14      0.7     
    Unknown                     38                                                             4.3    3      1.1    4      1.0    4      1.4    47     18.1   96      4.6     
  Nodal stage                                                                                                                                                                 
    Node negative               34                                                             3.8    16     6.0    18     4.5    17     6.0    6      2.3    91      4.3     0.931
    Node positive               281                                                            31.7   114    42.5   160    39.9   129    45.4   35     13.5   719     34.3    
    Unknown                     571                                                            64.4   138    51.5   223    55.6   138    48.6   218    84.2   1,288   61.4    
  Surgery                                                                                                                                                                     
    Yes                         181                                                            20.4   71     26.5   104    25.9   102    35.9   28     10.8   486     23.2    \<0.001^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    No                          700                                                            79.0   194    72.4   294    73.3   181    63.7   230    88.8   1,599   76.2    
    Unknown                     5                                                              0.6    3      1.1    3      0.7    1      0.4    1      0.4    13      0.6     
  Liver metastases only                                                                                                                                                       
    Yes                         209                                                            23.6   104    38.8   112    27.9   89     31.3   57     22.0   571     27.2    \<0.001^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    No                          661                                                            74.6   157    58.6   281    70.1   191    67.3   190    73.4   1,480   70.5    
    Unknown                     16                                                             1.8    7      2.6    8      2.0    4      1.4    12     4.6    47      2.2     
  Bone metastases                                                                                                                                                             
    Yes                         285                                                            32.2   130    48.5   145    36.2   147    51.8   92     35.5   799     38.1    \<0.001^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    No                          587                                                            66.3   132    49.3   246    61.3   133    46.8   152    58.7   1,250   59.6    
    Unknown                     14                                                             1.6    6      2.2    10     2.5    4      1.4    15     5.8    49      2.3     
  Lung metastases                                                                                                                                                             
    Yes                         317                                                            35.8   73     27.2   132    32.9   115    40.5   102    39.4   739     35.2    0.010^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    No                          541                                                            61.1   184    68.7   256    63.8   161    56.7   137    52.9   1,279   61.0    
    Unknown                     28                                                             3.2    11     4.1    13     3.2    8      2.8    20     7.7    80      3.8     
  Brain metastases                                                                                                                                                            
    Yes                         69                                                             7.8    25     9.3    33     8.2    38     13.4   25     9.7    190     9.1     0.042^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    No                          779                                                            87.9   235    87.7   348    86.8   237    83.5   207    79.9   1,806   86.1    
    Unknown                     38                                                             4.3    8      3.0    20     5.0    9      3.2    27     10.4   102     4.9     
  Status                                                                                                                                                                      
    Alive                       388                                                            43.8   144    53.7   246    61.3   65     22.9   76     29.3   919     43.8    \<0.001^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    Dead                        498                                                            56.2   124    46.3   155    38.7   219    77.1   183    70.7   1,179   56.2    
  Cause of death                                                                                                                                                              
    Alive                       313                                                            35.3   137    51.1   223    55.6   54     19.0   57     22.0   784     37.4    \<0.001^[b](#tfn2-mco-0-0-1890){ref-type="table-fn"}^
    Cancer                      535                                                            60.4   122    45.5   169    42.1   227    79.9   197    76.1   1,250   59.6    
    Other                       38                                                             4.3    9      3.4    9      2.2    3      1.1    5      1.9    64      3.1     

Patients of unknown statuses were excluded from the comparative analysis.

P\<0.05. HER2, human epidermal growth factor receptor 2; HR, hormone receptor.

###### 

Unadjusted OS.

                                                                                                                                         95% CI for Hazard ratio   
  ----------------------- ---- ------------------------------------------------------- ------------------------------------------------- ------------------------- -------
  Age                          \<0.001^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                               
    \<50                  31                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    50--64                31                                                           1.024                                             0.756                     1.387
    \>64                  19                                                           1.933                                             1.423                     2.626
  Sex                          NA                                                                                                                                  
    Male                  NA                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Female                NA                                                           NA                                                NA                        NA
  Race                         0.324                                                                                                                               
    Caucasian             29                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    African descent       26                                                           1.190                                             0.891                     1.590
    Others                24                                                           1.280                                             0.815                     2.011
  Marital                      0.018^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                                 
    Unmarried             19                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Married               30                                                           0.720                                             0.547                     0.949
  Insurance                    0.310                                                                                                                               
    Uninsured             10                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Insured               27                                                           0.638                                             0.263                     1.546
  Size (mm)                    0.036^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                                 
    ≤20                   33                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    21--50                29                                                           1.084                                             0.752                     1.565
    \>50                  23                                                           1.447                                             1.002                     2.090
  Grade                        0.033^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                                 
    I                     41                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    II                    34                                                           1.525                                             0.698                     3.330
    III/IV                23                                                           2.019                                             0.950                     4.292
  Laterality                   0.616                                                                                                                               
    Left                  26                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Right                 27                                                           1.063                                             0.836                     1.350
  Nodal stage                  0.360                                                                                                                               
    Node negative         33                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Node positive         26                                                           1.186                                             0.819                     1.716
  Surgery                      0.009^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                                 
    No                    25                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Yes                   31                                                           0.728                                             0.571                     0.927
  Liver metastases only        \<0.001^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                               
    Yes                   33                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    No                    24                                                           1.563                                             1.221                     2.002
  Bone metastases              0.003^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                                 
    No                    31                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Yes                   24                                                           1.433                                             1.127                     1.823
  Lung metastases              0.001^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                                 
    No                    30                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Yes                   22                                                           1.529                                             1.171                     1.998
  Brain metastases             0.030^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                                 
    No                    27                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Yes                   4                                                            1.912                                             1.045                     3.500
  Subtypes                     \<0.001^[b](#tfn4-mco-0-0-1890){ref-type="table-fn"}^                                                                               
    Her2^−^/HR^+^         24                                                           1^[a](#tfn3-mco-0-0-1890){ref-type="table-fn"}^                             
    Her2^+^/HR^−^         49                                                           0.477                                             0.315                     0.721
    Her2^+^/HR^+^         51                                                           0.456                                             0.318                     0.654
    Triple negative       15                                                           1.931                                             1.455                     2.563

1, reference value.

P\<0.05. CI, confidence interval; Her2, human epidermal growth factor receptor 2; HR, hormone receptor; NA, not applicable; OS, overall survival.

###### 

Multivariable Cox regression for all-cause mortality and cancer-specific mortality among patients with liver metastases.

                      All-cause mortality                               Cancer-specific mortality                                                                                 
  ------------------- ------------------------------------------------- ------------------------------------------------------- ------------------------------------------------- -------------------------------------------------------
  Age                 1.028 (1.018--1.038)                              \<0.001^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^   1.020 (1.010--1.030)                              \<0.001^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^
  Sex                                                                                                                                                                             
    Male              1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Female            12,885.534 (0.000--1.253×10^131^)                 0.949                                                   5,933.994 (1,381.922--2.55E+04)                   NA
  Race                                                                                                                                                                            
    Caucasian         1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    African descent   1.076 (0.795--1.458)                              0.635                                                   0.936 (0.699--1.250)                              0.660
    Others            1.478 (0.915--2.390)                              0.110                                                   1.630 (1.043--2.550)                                0.032^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^
  Marital                                                                                                                                                                         
    Unmarried         1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Married           0.687 (0.512--0.922)                              0.012^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^     0.744 (0.559--0.990)                                0.042^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^
  Insurance                                                                                                                                                                       
    Uninsured         1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Insured           0.586 (0.230--1.495)                              0.263                                                   0.594 (0.257--1.370)                              0.220
  Size (mm)                                                                                                                                                                       
    ≤20               1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    21--50            0.932 (0.636--1.366)                              0.719                                                   0.861 (0.603--1.230)                              0.410
    \>50              1.073 (0.722--1.595)                              0.728                                                   0.960 (0.654--1.410)                              0.840
  Grade                                                                                                                                                                           
    I                 1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    II                2.107 (0.951--4.672)                              0.066                                                   1.753 (0.793--3.880)                              0.170
    III/IV            2.442 (1.119--5.333)                              0.025^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^     2.172 (0.997--4.730)                              0.051
  Laterality                                                                                                                                                                      
    Left              1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Right             1.142 (0.890--1.465)                              0.297                                                   0.958 (0.750--1.220)                              0.730
  Nodal stage                                                                                                                                                                     
    Node negative     1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Node positive     1.066 (0.715--1.589)                              0.754                                                   1.106 (0.743--1.650)                              0.620
  Surgery                                                                                                                                                                         
    No                1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Yes               0.652 (0.500--0.850)                              0.002^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^     0.728 (0.560--0.945)                                0.017^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^
  Bone metastases                                                                                                                                                                 
    No                1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Yes               1.322 (1.027--1.701)                              0.030^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^     1.293 (1.003 - 1.670)                               0.048^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^
  Lung metastases                                                                                                                                                                 
    No                1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Yes               1.190 (0.898--1.577)                              0.227                                                   1.305 (0.998--1.700)                              0.051
  Brain metastases                                                                                                                                                                
    No                1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Yes               2.763 (1.467--5.205)                              0.002^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^     3.063 (1.493--6.280)                                0.002^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^
  Subtypes                                                                                                                                                                        
    Her2^−^/HR^+^     1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^                                                           1^[a](#tfn5-mco-0-0-1890){ref-type="table-fn"}^   
    Her2^+^/HR^−^     0.474 (0.309--0.725)                              0.001^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^     0.429 (0.277--0.665)                              \<0.001^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^
    Her2^+^/HR^+^     0.420 (0.289--0.610)                              \<0.001^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^   0.527 (0.367--0.755)                              \<0.001^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^
    Triple negative   2.024 (1.487--2.757)                              \<0.001^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^   2.098 (1.552--2.840)                              \<0.001^[b](#tfn6-mco-0-0-1890){ref-type="table-fn"}^

1, reference value.

P\<0.05. Abbreviations: CI, confidence interval; Her2, human epidermal growth factor receptor 2; HR, hormone receptor; NA, not applicable.

[^1]: Contributed equally
